

**Anti-ALP Reference Antibody (Seagen Patent Anti-Alpp)
Recombinant Antibody
Catalog # APR10060**

Specification

Anti-ALP Reference Antibody (Seagen Patent Anti-Alpp) - Product Information

Application	FC, E, FTA
Primary Accession	P05187-1
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	148.04 KDa

Anti-ALP Reference Antibody (Seagen Patent Anti-Alpp) - Additional Information

Target/Specificity

ALP

Endotoxin

< 0.001EU/ µg, determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.


Anti-ALP Reference Antibody (Seagen Patent Anti-Alpp) - Protein Information

Anti-ALP Reference Antibody (Seagen Patent Anti-Alpp) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-ALP Reference Antibody (Seagen Patent Anti-Alpp) - Images



Anti-ALP Reference Antibody (Seagen Patent Anti-Alpp) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-ALP Reference Antibody (Seagen Patent Anti-Alpp) is more than 97.51%, determined by SEC-HPLC.



Immobilized human ALPP His at 4 µg/mL can bind Anti-ALP Reference Antibody (Seagen Patent Anti-Alpp) $EC_{50}=0.004744 \mu\text{g/mL}$